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Activated CD8+ T cell extracellular vesicles prevent
tumour progression by targeting of lesional
mesenchymal cells
Naohiro Seo1,2, Yoshitaka Shirakura1, Yoshiro Tahara2,3, Fumiyasu Momose1,2, Naozumi Harada1,2,
Hiroaki Ikeda4, Kazunari Akiyoshi2,5 & Hiroshi Shiku1,2
Fibroblastic tumour stroma comprising mesenchymal stem cells (MSCs) and cancer-
associated ﬁbroblasts (CAFs) promotes the invasive and metastatic properties of tumour
cells. Here we show that activated CD8+ T cell-derived extracellular vesicles (EVs) interrupt
ﬁbroblastic stroma-mediated tumour progression. Activated CD8+ T cells from healthy mice
transiently release cytotoxic EVs causing marked attenuation of tumour invasion and
metastasis by apoptotic depletion of mesenchymal tumour stromal cells. Inﬁltration of EV-
producing CD8+ T cells is observed in neovascular areas with high mesenchymal cell density,
and tumour MSC depletion is associated with preferential engulfment of CD8+ T cell EVs in
this setting. Thus, CD8+ T cells have the capacity to protect tumour progression by EV-
mediated depletion of mesenchymal tumour stromal cells in addition to their conventional
direct cytotoxicity against tumour cells.
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A wide variety of cells including immune cells releasediverse types of extracellular vesicles (EVs) of endosomeand plasma membrane origin known as exosomes and
microvesicles with sizes 40–150 nm and 100–1000 nm,
respectively1,2. Physiologically active substances including various
proteins and nucleic acids (e.g., cytokines, mRNAs, microRNAs
[miRNAs]) are found in EVs and they act as central mediators of
the regulation of neighbouring and distant-recipient cells with
incorporated EVs3,4.
Dendritic cell (DC)-derived EVs directly enhance the antigen-
speciﬁc responses of CD4+ and CD8+ T cells and participate in
the activation of NK cells5. EV miRNAs from T cells are trans-
ferred into DCs in an antigen-speciﬁc manner6. In addition, it has
been reported that regulatory T cell-derived EVs act as sup-
pressors against pathogenic Th1 responses in an miRNA-
dependent manner7. These ﬁndings indicate that the parent cell
functions are inherited by EVs in part via miRNAs. Activated
CD8+ T cells have a central role in the exclusion of tumour cells
by direct interaction with tumour antigen peptides in the context
of MHC class I molecules8, suggesting that the derived EVs are
cytotoxic against tumour cells. Recently, it has been reported that
CD8+ T cells transmigrate into tumour lesions by releasing
granzyme B that mediates remodelling of the basement mem-
brane of tumour blood vessels9. This report suggested that CD8+
T cells have a tumoricidal function that involves an unknown
mechanism in addition to direct tumour cell killing, e.g., cyto-
toxicity against tumour stromal cells, modulation of tumour
angiogenesis and/or vascularisation, intrusion into tumour or
tumour stromal areas and prevention of tumour invasion and
metastasis by acquisition of mesenchymal-like properties in part
in an EV-mediated fashion.
Tumour stroma is formed by various inﬁltrating and locally
differentiated cell populations, e.g., tumour-associated macro-
phages (TAMs: F4/80+), DCs (CD11c+), myeloid-derived sup-
pressor cells (MDSCs: CD11b+ and granulocyte receptor
[Gr]-1+), cancer-associated ﬁbroblasts (CAFs: ﬁbroblast markers
[e.g., murine ER-TR7+] and α-smooth muscle actin [SMA]+), and
mesenchymal stem cells (MSCs: platelet-derived growth factor-α
[PDGFRα: CD140a]+ and stem cell antigen [Sca]-1+)10 along
with tumour angiogenesis (Sca-1+ and CD31+)11 to ﬁll gaps in
tumour areas with extracellular matrix proteins12,13. During the
malignant transformation process, tumour cells acquire
mesenchymal-like features that enable metastatic migration into
blood vessels and invasive spreading through the tumour capsule.
This process is mainly caused by transforming growth factor
(TGF)-β-mediated complicated molecular mechanisms12,14,15
and EV-dependent actions between tumour cells and tumour
stromal cells such as MSCs and CAFs2,16–21.
In this study, we investigated whether EVs from activated
CD8+ T cells are involved in the regulation of tumour progression
by intratumoural (i.t.) administration, and found that activated
CD8+ T cells from healthy mice interrupt tumour invasion and
metastasis by depleting tumoural mesenchymal cells.
Results
Depletion of mesenchymal stroma in CD8 EV-treated tumour.
To clarify the involvement of EVs from activated CD8+ T cells in
direct tumour cell killing, various cultured tumour cell lines were
mixed with EVs. Splenocytes from mutated (m) ERK2 peptide (a
H-2Kd-restricted epitope for CMS5a tumour cells)-speciﬁc TCR
gene-transgenic DUC18 mice22 or BALB/c mice splenocytes were
cultured, and the supernatants were used as a source of EVs from
tumour-speciﬁc or nonspeciﬁc CD8+ T cells, respectively (Sup-
plementary Fig. 1a: DUC18 CD8 EV or BALB CD8 EV). As
shown in Supplementary Figs. 1b–d, 2, 3a, b, 10a and 12d,
DUC18 CD8 EVs and BALB CD8 EVs failed to modulate various
tumour cell lines. Next, we investigated in detail the role of
activated CD8+ T cell EVs against tumour tissues.
Growth of subcutaneous CMS5a tumours (1.0–1.2 cm tumour
diameter) was signiﬁcantly attenuated in DUC18 CD8 EV- and
BALB CD8 EV-treated groups by i.t. administration compared to
BALB CD4 EV (from CD8+ cell-depleted BALB/c splenocytes)-,
CMS5a EV- or hPBMC EV-treated groups (Supplementary
Fig. 4a). Spheroid formation observed after cultivation (24 h)
of CMS5a tumour suspensions disappeared in DUC18 CD8
EV-treated cases (Supplementary Fig. 4b). Growth of CT26 on
BALB/c mice or B16 on B6 mice was also attenuated by i.t.
treatment with DUC18 CD8 EVs (Supplementary Fig. 4c).
Furthermore, the attenuated growth of DUC18 CD8 EV- and
BALB CD8 EV-treated CMS5a was visualised by Ki-67 staining
(Supplementary Fig. 4d). Collectively, these results indicate that
activated CD8+ T cells, but not activated CD4+ T cells, tumour
cells or human CD8+ T cells, release EVs that downregulate
tumour growth and reduce in vitro spheroid formation.
Next, we examined the ﬂuctuation of cell populations reported
as regulators of tumour progression. Although the proportion of
CD4+ cells, CD8+ cells, macrophages, DCs or MDSCs were not
changed in EV-treated CMS5a tumours (Supplementary Fig. 5),
the expression of CD140a and TGF-β was markedly decreased in
association with the disappearance of MSC and CAF areas on day
3 after i.t. administration of DUC18 CD8 and BALB CD8 EVs
(Figs. 1a−c). The time-course study of functional EV production
was performed using CD8+ T cell EVs from both B16 melanoma-
associated both TRP-2 peptide- and gp100 peptide-stimulated
B6 splenocytes (B6 CD8 EVs). The B16-speciﬁc CD8+ T cell
population gradually increased during cultivation and comprised
95 and 3%, respectively, of the CD8+ populations on day 15
(Supplementary Fig. 6). Notably, the reduction of CD140a
expression peaked when EVs from the 7-day cultured CD8+
T cells were applied to unrelated CMS5a as well as to relevant B16
tumours (Fig. 1d). There was no difference in tumour growth or
tumour cell populations including MSCs and CAFs after
intratumoural treatment of EVs from cultured CMS5a-bearing
BALB/c CD8+ splenocytes (BALB TB CD8 EVs) (Supplementary
Figs. 5, 7a–c and 10a), indicating the importance of the biological
conditions as well as the culture period for CD8+ T cells to release
functional EVs.
To conﬁrm the anti-mesenchymal stromal nature of CD8+ T
cell-derived EVs in vivo, MSCs were cultured from crushed femur
bones of Thy-1.1+ BALB/c congenic mice (Supplementary
Fig. 8a–c), and Thy-1.1+ MSC-chimeric BALB/c mice were
prepared by transferring cultured Thy-1.1+ MSCs into irradiated
Thy-1.2+ BALB/c mice (Supplementary Fig. 9). When DUC18
CD8 EVs and BALB CD8 EVs were injected into subcutaneous
CMS5a tumours in Thy-1.1+ MSC-chimeric BALB/c mice, nearly
all tumour Thy-1.1+ cells, including 5–7% of transferred CD140a+
Sca-1+ MSCs and 22% of MSC-differentiated cells, disappeared
(Fig. 1e). In conclusion, CD8+ T cells from healthy mice can
produce EVs that destroy mesenchymal tumour stroma in the
same species without H-2 restriction.
Reduced viability of cultured MSC by treatment with CD8 EV.
According to a procedure of camptothecin-induced programmed
death of Jurkat cells (Supplementary Fig. 11a)23, we examined
death of cultured MSCs by addition of CD8+ T cell EVs. The
number of cultured bone-derived MSCs was markedly decreased
with enhanced annexin V-staining intensity at 3 days after
treatment with DUC18 CD8 EVs, BALB CD8 EVs and B6 CD8
EVs, but not BALB TB CD8 EVs or BALB CD4 EVs in an acti-
vated caspase-3-mediated manner (Fig. 2a; Supplementary
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Fig. 10b). Furthermore, the generation of mesenchymal-like
CMS5a and B16 cells with augmented CD140a expression and
spheroid-forming capacity of CMS5a, 4T1, CT26 and B16 cells in
the presence of bone-derived MSCs were downregulated in the
presence of DUC18 CD8 EVs, but not BALB TB CD8 EVs
(Fig. 2b; Supplementary Fig. 11b). These results indicate that
progressive tumour cells generated by contact with MSCs were
disturbed by CD8+ T cell-derived EV-mediated depletion of
MSCs.
The cultured MSCs expressed Fas, whereas the cultured CMS5a
did not (Supplementary Fig. 12a), suggesting that death molecule
ligands, e.g., FasL, tumour necrosis factor (TNF)-α and
programmed death (PD)-L124,25, on EV surfaces are involved
in the depletion of MSCs. However, FasL, TNF-α or PD-L1
expression was not observed on DUC18 CD8 EVs or BALB CD8
EVs (Supplementary Fig. 12b and d), In addition, a FasL-
neutralising mAb did not restore DUC18 CD8 EV-mediated
depletion of cultured MSCs (Supplementary Fig. 12c).
After comparison of global-normalised law data from micro-
array analysis (3D-gene: Toray) among miRNAs from DUC18
CD8 EVs, BALB CD8 EVs, BALB TB CD8 EVs, bone-derived
MSCs, CMS5a and B16, we selected miR-298, 1943 and 5099 and
miR-150, 223 and 3470b as both DUC18 CD8 EV- and BALB
CD8 EV-dominant miRNAs and BALB TB CD8 EV-dominant
miRNAs, respectively (Supplementary Table 1). miR-298 and
-1943 have been reported to have a suppressive role against
tumour progression (Supplementary Fig. 12e). We synthesised six
miRNAs for transfection into cultured bone-derived MSCs
(Supplementary Fig. 10c). The number of MSCs was reduced
by introduction of miR-298 in an activated caspase-3-mediated
manner (Supplementary Fig. 10d), but not by introduction of
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Fig. 1 Depletion of tumour mesenchymal stroma by i.t. treatment with CD8+ T cell EVs. Expressions of CD140a in a CMS5a tumour (n= 4 per group)
treated intratumorally with/without BALB CD8 EVs, DUC18 CD8 EVs or BALB CD4 EVs (10 μg [5–7 × 108 vesicles]/tumour) are shown as histogram data
obtained by ﬂow cytometry (a) and representative photos of ﬂuorescent immunohistochemistry (b). Each photo is a representative of 4–5 photos. c
CMS5a tumour on day 3 after treatment with the indicated EVs (10 μg [5–7 × 108 vesicles]/tumour) were sectioned and dual stained with CD140a- and
Sca-1-speciﬁc mAbs, ER-TR7- and α-smooth muscle actin-speciﬁc mAbs, or TGF-β- and Sca-1-speciﬁc mAbs. Each photo is a representative of 5–6 photos.
The dotted circles express the overlapping areas of PE and FITC ﬂuorescence. The number of overlapping areas of DUC18 CD8 EVs (**) and BALB CD8 EVs
(*)-treated groups were signiﬁcantly different from the untreated group with p< 0.01 and p< 0.05, respectively (n.s., not signiﬁcant; error bars indicate
SEM). The data were analysed by a two-tailed unpaired Student t-test. d EVs (10 μg [5–7 × 108 vesicles]/tumour) prepared from day 5, 7, 10 or 15 culture
medium of both TRP-2 peptide and gd100 peptide-stimulated B6 splenocytes were injected into subcutaneous CMS5a or B16 tumours. Three days after EV
treatment, the CD140a expression in tumour cell suspensions was examined by ﬂow cytometric analysis. e CMS5a cells were inoculated subcutaneously
into Thy-1.1+ bone-derived MSC-chimeric BALB/c mice (n= 4 mouse per group). DUC18 CD8 EVs or BALB CD8 EVs (10 μg [5–7 × 108 vesicles]/tumour)
were injected into day 12 subcutaneous CMS5a tumours. 3 days after EV treatment, the % of CD140a+ and Sca-1+ cells and transferred Thy 1.1+ cells was
examined by ﬂow cytometry
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dominant miRNAs were not effective (Fig. 2c). In addition, the
levels of miR-298-5p in BALB CD8 EVs were conﬁrmed to be
higher than those in TB CD8 EVs from B16F10-bearing mice or
tumour cell-derived EVs (Supplementary Fig. 10e). These results
indicate that CD8+ T cells from normal mice, but not tumour-
bearing mice, release cytotoxic miRNA (miR-298-5p)-embedded
EVs to kill MSCs.
Dominant EV uptake by mesenchymal tumour stromal cell.
RNA-speciﬁc ﬂuorescence dye (SYTO RNASelect)-stained
DUC18 CD8 EVs were introduced into subcutaneous CMS5a or
B16 tumours. At 2 h after treatment, green ﬂuorescence of SYTO
RNASelect was observed in CD140a+ Sca-1+ mesenchymal cell
populations, including vascular tissues or peritumoral areas, but
not in other cell populations including tumour cells (Fig. 3a, b).
Unexpectedly, cultured CMS5a and B16 cells could not engulf
SYTO RNASelect-stained DUC18 CD8 EVs at 2 h after treat-
ment, whereas endocytic incorporation of SYTO RNASelect-
stained EVs was observed immediately in cultured bone-derived
MSCs (Fig. 3c). Consistent with the DUC18 CD8 EV ﬁndings,
SYTO RNASelect-stained BALB CD8 EVs and hPBMC EVs were
preferentially engulfed by MSCs compared to B16 or CMS5a
tumour cells (Supplementary Fig. 13). Indeed, exosomes appear
to have properties that cause preferential engulfment by
mesenchymal cells as shown in previous studies26,27.
Prevention of tumour invasion and metastasis by CD8 EV.
Destruction of the ﬁbroblastic mesenchymal stroma by CD8+ T
cell-derived EVs may be indirectly associated with the reduced
invasive and metastatic properties of progressive tumours20.
Subcutaneous B16F10, 4T1 or CMS5m tumour was treated with
DUC18 CD8 EVs, BALB CD8 EVs, BALB CD4 EVs or BALB TB
CD8 EVs at 10, 13 and 16 days after tumour inoculation (Fig. 4a).
On day 18, each subcutaneous tumour was carefully removed to
observe tumour invasion. In the 50% of untreated, 66.7% of BALB
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Fig. 2 Reduced viability of cultured MSCs by CD8+ T cell EVs. a DUC18 CD8 EVs, BALB CD8 EVs, B6 CD8 EVs, BALB TB CD8 EVs or BALB CD4 EVs were
added to bone-derived MSC cultures at the indicated doses. Three days after EV treatment, bone-derived MSCs (n= 5 per group) were stained with anti-
CD140a mAb and annexin V and subjected to ﬂow cytometric analysis. b CMS5a and B16 cells were cultured with bone-derived MSCs for 4 days in the
presence of DUC18 CD8 EVs at the indicated doses (n= 4 per group). The obtained tumour cells were analysed for CD140a expression by ﬂow cytometry.
c Selected miR-298-5p, -1943-3p and -5099 as both DUC18 CD8 EV- and BALB CD8 EV-dominant miRNAs were synthesised and transfected alone or in a
mixture by lipofection into bone-derived MSCs (n= 4 per group). Synthetic BALB TB CD8 EV-dominant miRNAs (miR-150, 223-3p or 3470b) were used as
controls (n= 4). 3 days after transfection, the obtained bone-derived MSCs were stained with CD140a- and Sca-1-speciﬁc mAbs and annexin V (d), and
subjected to ﬂow cytometric analysis to assess the total number of cultured MSCs
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groups, or 50% of untreated and 60% of BALB CD4 EV-treated
4T1 groups, it was impossible to completely remove the tumours
and these tumours invaded into the muscle or fatty layer (Fig. 4b;
Table 1). Inversely, no invasion of B16F10, 4T1 or CMS5m was
observed following treatment with DUC18 CD8 EVs. All
remaining mice were able to remove the tumour completely
(Table 1). Disappearance of the CD140a+ Sca-1+ mesenchymal
stromal areas in the DUC18 CD8 EV- and BALB CD8 EV-treated
groups was observed in day 18 B16F10 sections (Fig. 4c).
Intratumoural DUC18 CD8 EV and BALB CD8 EV treatments
showed a marked decrease in the number of colonies of B16F10
or CMS5m lung metastasis compared to those from untreated,
BALB CD4 EV- or CMS5a EV-treated case in wild-type or nude
mice studies (Fig. 5; Supplementary Fig. 14a and b). These results
highlight the inhibitory roles of CD8+ T cell-derived EVs on
mesenchymal cell-mediated tumour invasion and metastasis.
Destruction of tumour stroma by activated CD8+ T cell. We
then investigated whether tumour-inﬁltrating CD8+ T cells can
destroy the mesenchymal stromal structure in an EV-mediated
manner. Thy-1.1+ DUC18 CD8+ T cells were cultured with/
without GW4869 (an inhibitor of exosome production) and
transferred intravenously into CMS5a-bearing mice. Thy-1.1+
DUC18 CD8+ T cell-derived EVs strongly expressed CD9 and
Thy-1.1 and minimally expressed CD8 (Fig. 6a). GW4869-treated
Thy-1.1+ DUC18 CD8+ T cells exhibited lower EV production
(Fig. 6b), whereas the degree of inﬁltration into subcutaneous
CMS5a tumours was comparable to the untreated control
(DMSO-treated) on the day after intravenous transfer (Fig. 6c, left
large photo), indicating that tumour inﬁltration of CD8+ T cells
was not altered by GW4869 treatment. The blurred ﬂuorescence
of EV-originated Thy-1.1 and CD9 was not visible around
tumour-inﬁltrating GW4869-treated Thy-1.1+ DUC18 CD8+
T cells (Fig. 6c, right two small photos). The white signals of EV-
originated green Thy-1.1 merged with purple CD140a+ Sca-1+
MSC areas were frequently observed in GW4869-untreated Thy-
1.1+ DUC18 CD8+ T cell-inﬁltrating CMS5a tumours (Fig. 6d),
demonstrating tumour-inﬁltrating CD8+ T cell-derived EV
uptake by tumour mesenchymal cells.
Interestingly, DUC18 CD8+ T cells, regardless of GW4869
treatment, entered CMS5a tumour lesions through the Sca-1+
CD31+ VCAM-1+ neovascular areas, where stromal endothelial
progenitor cells (CD31+ Sca-1+) and MSCs (CD140a+ Sca-1+)
were abundantly observed (Fig. 7a, b; Supplementary Fig. 15a–c)
on the day after intravenous treatment. CD140a+ Sca-1+
mesenchymal stromal areas of CMS5a tumours in BALB/c
wild-type or nude mice disappeared on day 3 after transfer of
GW4869-untreated Thy-1.1+ DUC18 CD8+ T cells (Fig. 7c) and
persisted thereafter (Fig. 7c: in BALB/c wild-type), demonstrating
a correlation between tumour inﬁltration of EV-producing CD8+
T cells and depletion of the mesenchymal stroma.
Discussion
CD8+ T cell-derived EV-mediated depletion of mesenchymal
tumour stromal cells including MSCs and CAFs leads to vigorous
attenuation of tumour progression as shown by the loss of
a
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Fig. 3 Rapid engulfment of EV RNAs by mesenchymal cells. a SYTO RNASelect-stained DUC18 CD8 EVs (10 μg [5–7 × 108 vesicles]/tumour) were injected
into CMS5a and B16 tumours (n= 3 per group). At 2 h after treatment, the cell suspensions from resected tumours were stained with PE-CD140a- and
APC-Sca-1-speciﬁc mAbs, and analysed for SYTO RNASelect-derived green ﬂuorescence in the CD140a+ Sca-1+ population or other cells, including tumour
cells, by ﬂow cytometry. b SYTO RNASelect-stained DUC18 CD8 EVs (10 μg [5–7 × 108 vesicles]/tumour) were injected into CMS5a tumours (n= 3).
At 2 h after treatment, the obtained tumours were sectioned and stained with PE-CD140a or PE-Sca-1-speciﬁc mAb. Each photo is a representative of 4–5
photos. The dotted circles indicate the overlapping areas of PE-originated red and SYTO RNSelect-derived green ﬂuorescence. c SYTO RNASelect-stained
DUC18 CD8 EVs (5 μg [4 × 108 vesicles]/mL) were added to in vitro cultured B16, CMS5a or bone-derived MSCs (n= 5 per group). Two hours later, the
cells were treated with lysotracker (blue), and then observed by confocal laser scanning microscopy. Each photo is a representative of images in 3–4 areas
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invasive and metastatic properties (Supplementary Fig. 16).
Recently, it has been reported that tumour stem cells char-
acterised as mesenchymal-like invasive tumour cells can be
reprogrammed into an epithelial state by cyclic (c) AMP-
mediated activation of protein kinase A (PKA) and subsequent
epigenetic promotion of epithelial-related genes by histone
demethylase28. Consequently, destruction of mesenchymal
tumour stroma by CD8+ T cell EVs may elicit mesenchymal-to-
epithelial transition of invasive tumours in a cAMP/PKA-medi-
ated manner, but it remains unclear whether unknown actions,
including reduction of TGF-β expression, participate in this
tumour reprogramming. In contrast, we found that the culture
period and biological conditions are pivotal factors in obtaining
functional EVs. It was previously reported that the quality and
quantity of antigen-presenting efﬁcacy of DC-derived EVs is
inversely correlated with the maturation process of DCs in a
culture system29,30. Thus, it is necessary to explore a wide variety
of culture conditions to obtain functional immune cell-derived
EVs. Our ﬁndings indicate that targeting of certain EVs from
CD8+ T cells to mesenchymal tumour stromal cells is useful for
future treatment of patients with metastatic refractory tumours,
including pancreatic cancer.
In addition to the central effect against malignancy by speciﬁc
interactions with tumour cells17,31,32, we demonstrated that
CD8+ T cells are involved in restoration of the tumour micro-
environment by EV-mediated regulation of mesenchymal tumour
stroma. miR-298–5p in CD8+ T cell EVs is one of the molecules
involved in the depletion of tumoural mesenchymal cell popu-
lations, although it is necessary to elucidate the mechanism of
action including identiﬁcation of target genes. In addition to EV-
embedded cytotoxic miRNA, death molecule ligands such as
FasL, TNF-α and PD-L1 on CD8+ T cell EVs are candidates for
depletion of tumour stromal mesenchymal cells. However, these
molecules are not expressed on CD8+ T cell EVs. Future studies
should examine the involvement of cytotoxic molecules, e.g.,
granzyme B, in CD8+ T cell EVs as indicated in Supplementary
Fig. 2 and reported by other groups in studies of NK cell EVs33,34.
Circulating MSCs are primarily retained near tumour neo-
vascularization and angiogenesis sites as pericytes to protect
blood walls35. In addition, the differentiation of tumour-
inﬁltrating MSCs to myoﬁbroblasts is promoted by neovascu-
lature development-related cytokines5,36. Thus, formation of the
mesenchymal tumour stromal structure is strongly associated
with the angioarchitecture. As observed in (Fig. 7b), activated
tumour-speciﬁc CD8+ T cell inﬁltration into the tumour stromal
a
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Fig. 4 Inhibition of tumour invasion by i.t. treatment of CD8+ T cell EVs. a Time schedule of the observation of subcutaneous tumour invasion. At days 10,
13 and 16 after subcutaneous B16F10, 4T1 or CMS5m inoculation, DUC18 CD8 EVs, BALB CD8 EVs or BALB CD4 EVs were injected intratumorally (10 μg
[5–7 × 108 vesicles]/tumour/day). b B16F10, 4T1 or CMS5m tumours on day 18 were sectioned and stained with haematoxylin and eosin (T tumour area,
ML muscle layer, FL fatty layer). c B16F10 tumours on day 18 were sectioned and stained with PE-CD140a and FITC-Sca-1-speciﬁc mAbs and DAPI. Each
photo is a representative of 3–4 photos of each group. The number of overlapping areas of PE and FITC ﬂuorescence of DUC18 CD8 EV and BALB CD8 EV-
treated groups (*) were signiﬁcantly different from the untreated group (n= 7) with p< 0.05. The data were analysed by a two-tailed unpaired Student t-
test. n.s. not signiﬁcant
Table 1 Reduced B16F10 or 4T1 invasion after i.t. treatment
of CD8+ T cell EVs
I.t. treatment No. of mice with B16F10
invasion/total mice (%)
No. of mice with 4T1
invasion/total mice (%)
Untreated 6/12 (50%) 2/4 (50%)
DUC18 CD8 EV 0/13 (0%) 1/5 (20%)
BALB TB CD8 EV 2/3 (66.7%) n.t.
BALB CD8 EV 0/3 (0%) n.t.
BALB CD4 EV 2/5 (40%) 3/5 (60%)
n.t. not tested
Number of B16F10- or 4T1-bearing mice with muscle and/or fatty layer invasion beyond the
tumour tissues (impossible to remove the subcutaneous tumours surgically) was counted
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areas with neovascularization in which epithelial progenitor cells
(EPCs) concomitantly accumulate from the periphery37 is mor-
phologically convenient for EV-mediated elimination of
mesenchymal tumour stroma. GW4869 is known to attenuate
production of inﬂammatory cytokines such as interleukin (IL)-1β,
IL-6 and TNF-α of macrophages38. Therefore, GW4869-treated
CD8+ T cells that reduced cytokine production may regulate
tumour angiogenesis without affecting their tumour inﬁltration.
In addition to the abnormalities of tumour blood vessels and
interstitial pressure towards the vessel lumen, reduced expression
of adhesion molecules for rolling and ﬁrm adhesion of lympho-
cytes on tumoural endothelial cells (e.g., intercellular adhesion
molecule-1 and -2 for lymphocyte function-associated antigen-1,
and vascular adhesion molecules [VCAM]-1 for very late antigen
[VLA]-4) is the cause of impaired extravasation of lymphocytes
into tumour lesions39–42. Down-regulation of adhesion molecules
on endothelial cells is induced by chronic stimulation with
angiogenic factors such as basic ﬁbroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF)43. Our results
regarding inﬁltration of transferred CD8+ T cells at the tumour
neovascularization sites show the successful extravasation of the
transferred CD8+ T cells via new tumour blood vessels where
endothelial cells still bear adhesion molecules because of a lack of
continuous stimulation with bFGF and VEGF. A previous study
demonstrated the necessity of EPC activation via VCAM-1 sig-
nalling in the extravasation of VLA-4-expressing lymphocytes44.
Methods
Mice and tumour cell lines. Female B6 and BALB/c mice were purchased from
Japan SLC. Congenic BALB/c Thy-1.1 mice with mutated ERK2 (mERK2) 136-144
(QYIHSANVL)-speciﬁc H-2Kd-restricted TCR (Vα10.1/Jα48 and Vβ8.3/Dβ2.1/
Jβ2.6) gene-transfected DUC18 mice, and Congenic DUC18 Thy-1.1 mice were
bred and maintained in a speciﬁc pathogen-free vivarium at Mie University
Institute of Laboratory Animals. All mice were used at 7–9 weeks of age. In all
experiments, tumour-bearing mice were randomly allocated to experimental
groups. In experiments where in vivo assays were performed, the variation within
groups allowed the detection of differences with 4–5 mice per group. CMS5a,
CMS5m, CMS7, CT26, 4T1, B16 and B16F10 tumour cell lines were maintained in
D-MEM medium supplemented with 10% foetal calf serum (FCS). Jurkat E6-1 cell
line was cultured in RPMI-1640 medium supplemented with 10% FCS. All cell
lines were purchased from ATCC and were found to be negative for mycoplasma
contamination. Experimental protocols were approved by the Animal Ethics
Committee of Mie University, Tsu, Japan (Approval number 23–8). The human
study was conducted in accordance with the current version of the Declaration of
Helsinki. Written informed consent was obtained from all healthy donors parti-
cipating in this study. The experimental protocols were approved by the Ethics
Review Committees of the Mie University, Tsu, Japan (Approval No.: 2879).
Preparation of EVs from culture media. EV-free FCS (dFCS) was prepared by
centrifugation of FCS at 100,000 × g for 18 h followed by ﬁltration (0.45 and 0.22
nm). Splenocytes (2 × 107 cells/mL) from DUC18 and Thy-1.1 DUC18 mice were
cultured in RPMI-1640 supplemented with 10% dFCS and 1 µg/mL mERK2 pep-
tides. Splenocytes (2 × 107 cells/mL) from B6 mice were cultured in RPMI-1640
supplemented with 10% dFCS and 1 µg/mL each of TRP-2 (SVYDFFVWL) and
gp100 (EGSRNQDWL) peptides45. Splenocytes (2 × 107 cells/mL) from BALB/c,
2 weeks subcutaneous CMS5a- or B16F10-bearing BALB/c, or CD8+ T cell-
depleted BALB/c mice were cultured with RPMI-1640 supplemented with 10%
dFCS and 1 µg/mL anti-CD28 mAb (37.51: eBioscience) in anti-CD3 mAb (2C11:
2 µg/mL: Biolegend)-immobilised 12-well plates. CD8+ hPBMCs separated nega-
tively with hCD4-beads (Miltenyi Biotec) were cultured with RPMI-1640 supple-
mented with 10% dFCS and 1 µg/mL CD28.2 mAb (Biolegend) in OKT3 mAb (2
µg/mL: Biolegend)-immobilised 12-well plates. CD8+ T cell-depleted BALB/c mice
were prepared by intravenous injection of a Lyt-2.2-speciﬁc mAb (400 μg/mouse)
to expand CD4+ T cells in vitro. After 4 days of cultivation, each culture medium
was changed to RPMI-1640 supplemented with 10% dFCS and recombinant (r) IL-
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Fig. 5 Inhibition of tumour metastasis by i.t. treatment of CD8+ T cell EVs. a Time schedule of the observation of B16F10 lung metastasis. b Lung metastasis
of B16F10 tumours on day 45 from the indicated groups (n= 7 per group) was examined, and the numbers of metastatic tumour colonies were counted
(**p< 0.01; error bars indicate SEM). The data were analysed by two-tailed unpaired Student t-test. c Time schedule of the observation of CMS5m lung
metastasis. d Lung metastasis of CMS5m tumours on day 47 (n= 6 per group) from the indicated groups was examined, and the numbers of metastatic
tumour colonies were counted (**p< 0.01; error bars indicate SEM). The data were analysed by a two-tailed unpaired Student t-test
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cultured cells were subjected to ﬂow cytometric analysis using murine anti-CD4
(GK1.5), CD8 (53–6.7), TCRVβ (H57–597), TCRVβ8.3 (1B3.3), CD9 (MZ3), CCR7
(4B12), FasL (Kay-10), PD-1 (RMP1-30), CD40L (MR1) or TIM-3 (RMT3–23)
mAb, or human CD4 (OKT4), CD8 (RPA-T8) and TCRαβ (IP26)-speciﬁc mAbs
(all from Biolegend).
The obtained culture supernatants (approximately 500 mL) were ﬁrst
centrifuged at 10,000×g for 20 min, ﬁltrated through 0.45- and 0.22-μm ﬁlters, and
subjected to ultraﬁltration to concentrate the sample to 100 mL (Kvick Lab Packet
50 KD: GE Healthcare). The concentrated culture supernatants were further
ﬁltrated through a 0.22-μm ﬁlter and subjected to ultracentrifugation for 2 h at
100,000×g (SW28 rotor: Beckman Coulter). The obtained EV pellets were
suspended in PBS, recentrifuged at 100,000×g, dissolved in 0.5–2 mL PBS, and
stored at 4 °C.
The protein concentrations of the puriﬁed EVs and parent cells were assessed
using the bicinchoninic acid (BCA) protein assay kit (Pierce). The mean number
and diameter of puriﬁed EVs were measured by using a nano-tracking system
(LM10-HS: NanoSight). EV surface proteins were detected by ﬂow cytometric
analysis of the latex beads-bound EVs stained with ﬂuorescein isothiocyanate
(FITC) or phycoerythrin (PE)-conjugated anti-CD4, CD8, CD9, CD63 (NVG-2),
Vβ8.3 (1B3.3), CCR7, FasL, PD-1, CD40L or TIM-3 mAb (all from Biolegend).
Polystyrene latex beads (10 μm diameter) were mixed with EV solutions at a ratio
of 3 particles/latex bead in 0.1 M 2-morpholinoethanesulfonic acid buffer,
incubated for 2 h on a rotating shaker, and then blocked with 400 mM glycine. The
obtained latex bead-bound EVs were washed twice with PBS containing 2% dFCS
and subjected to staining with mAbs.
To investigate the kinetics of EVs in vivo and in vitro, 100–300 µg of EVs were
incubated with 10 µM SYTO RNASelect (Molecular Probes) at 37 °C for 20 min,
and then subjected to a Spehadex-G25 spin column to exclude free dye.
Preparation of bone-derived MSCs. Bone-derived MSCs were prepared from
bone-marrow-cell ﬂushed thighbones (femurs) according to the manufacturer’s
directions (StemCell Technologies). Both ends of 10 femurs from BALB/c or Thy
1.1+ BALB/c mice were cut down and transferred into a mortar in 5 mL of PBS
containing 1% bovine serum albumin (BSA) and crushed by gentle stirring with a
pestle for 5 min to remove as many red bone marrow cells as possible. After 5
cycles of removing red bone marrow cells, the fragmented white femurs were
collected and incubated with PBS supplemented with 0.2% collagenase type I
(Sigma). After vigorous shaking at 37 °C for 40 min in a water bath, the super-
natants containing MSCs were washed three times with PBS. Dish-adherent MSCs
were cultured for 30 days in mouse MesenCult MSC basal medium supplemented
with 20% MSC stimulatory supplement (StemCell Technology), with the medium
changed every other day. The potential of the obtained MSCs to differentiate into
adipocytes and osteocytes was tested by using 70% conﬂuent MSCs in MesenCult
MSC basal medium supplemented with 20% adipogenic and osteogenic stimulatory
supplements for 2 weeks, and then staining with Oil Red O (Sigma-Aldrich) for
adipocytes and Alizarin Red S (Wako Pure Chemical Industries) for osteocytes.
Colony formation in primary MSCs cultivated in MSC stimulatory supplement-
containing medium was observed after staining with Giemsa (Wako Pure Chemical
Industries). The purity of cultured bone-derived MSCs was conﬁrmed to be over
95% by ﬂow cytometric analysis (FACScant II: BD Biosciences) using both PE-
conjugated anti-CD140a and FITC-conjugated anti-Sca-1 mAbs. For more precise
analysis of the cultured MSCs, the positivity of CD29 and CD105 and negativity of
CD14, CD19, CD34 and CD45 of MSCs were analysed by ﬂow cytometry using
each molecule-speciﬁc mAbs (all from Biolegend).
Preparation of bone-derived MSC-chimeric mice. Bone marrow cells were
prepared by marrow ﬂushing of the femurs of BALB/c mice (Thy-1.2) as described
above. BALB/c mice were irradiated at 6 Gy before cultured MSC transplantation.
The cultured bone-derived MSCs from Thy-1.1+ BALB/c mice (1 × 106) were
mixed with 5 × 106 cells of bone marrow cells from BALB/c femurs, transferred
intravenously into irradiated BALB/c mice, and the resulting chimeric mice were
maintained with autoclaved water containing 1 mg/mL neomycin sulphate (Cal-
biochem) and X-ray-sterilised food for over 2 weeks. At 60 days after MSC transfer,
Thy-1.1+ bone-derived MSC-chimeric BALB/c mice were used to conﬁrm tumour
MSCs.
Treatment with CD8+ T cells and EVs in vivo. 10 days after tumour inoculation
(approximately 10 mm tumour diameter), CMS5a-bearing BALB/c or BALB/c
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Fig. 6 EV production by adoptive transferred tumour-speciﬁc CD8+ T cells. a Cultured Thy-1.1+ DUC18 CD8 EV bound to latex beads were stained with the
indicated mAbs, and subjected to ﬂow cytometric analysis. b EV proteins from the supernatant of Thy-1.1+ DUC18 CD8+ T cells cultured with/without
GW4869 (DMSO treatment as a control) were measured by BCA assay (**p< 0.01; error bars indicate SEM) (n= 3). The data were analysed by a two-
tailed unpaired Student t-test. c Thy-1.1+ DUC18 CD8+ T cells cultured with/without GW4869 were transferred intravenously into CMS5a tumour-bearing
BALB/c mice (n= 6 per group). The next day, resected CMS5a tumours were sectioned and stained with the indicated FITC-conjugated or PE-conjugated
mAbs and DAPI (c), or PE-conjugated CD140a-, FITC-conjugated Thy-1.1- and APC-conjugated Sca-1-speciﬁc mAbs (d). The stained tumour sections were
observed by ﬂuorescent microscopy (c) or confocal laser scattering microscopy (d). Each photo is a representative image from 3–5 areas. The dotted
circles and arrows indicate MSC areas (purple) and Thy-1.1+ EV-engulfed MSCs (white), respectively
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T cells (1 × 107 cells per mouse) with/without GW4869 treatment simultaneously
with intratumoral treatment of 1 µg per tumour anti-murine glucocorticoid-
induced TNF receptor-related protein mAb (DTA-1). DTA-1 was used as an
accelerator of CD8+ T cell accumulation at tumour sites46. GW4869 treatment was
performed at 20 μg/mL for 24 h before the end of culture. At 1, 2, 3, 5 and 7 days
after infusion, CMS5a tumour tissues were collected and subjected to ﬂuorescence
immunohistochemistry.
CMS5a, CT26 or B16 cells (1 × 106 cells per mouse) were inoculated
subcutaneously in the back skin of BALB/c or B6 mice, respectively. At 12 days
after the randomised and blinded allocation of all tumour-bearing mice, EVs were
treated intratumorally (10 μg [5–7 × 108 vesicles]/tumour), and subsequent tumour
diameter was measured. Alternatively, 3 days after EV treatment, the excised
tumours were cut out with scissors and then incubated in PBS containing 0.5%
trypsin and 1 mM EDTA at 37 °C for 60 min. The obtained tumour cell
suspensions were passed through wool columns, washed three times with PBS
containing 1% FCS, and then subjected to ﬂow cytometric analysis using FITC-
conjugated mAbs speciﬁc for Sca-1, I-Ad, CD11b CD11c, CD73 or CD206 and PE-
conjugated mAb speciﬁc for F4/80, Gr-1 or CD140a (all from Biolegend), or
cultivation with RPMI-1640 supplemented with 10% FCS (1 × 105 cells/mL) to
evaluate spheroid formation.
EVs (10 μg [5–7 × 108 vesicles]/tumour) were injected i.t. in CMS5a-bearing
Thy-1.1+ bone-derived MSC-chimeric BALB/c mice 2 weeks after subcutaneous
CMS5a inoculation. The suspensions of tumour cells obtained 3 days after EV
treatment were stained with FITC-conjugated Thy-1.1-speciﬁc mAb, PE-
conjugated CD140a-speciﬁc mAb, and/or allophycocyanin (APC)-conjugated Sca-
1-speciﬁc mAb and subjected to ﬂow cytometric analysis after exclusion of 7-
aminoactinomycin D (all from Biolegend)-stained cells.
DUC18 CD8 EVs, BALB CD8 EVs, BALB CD4 EVs or CMS5a EVs (10 μg
[5–7 × 108 vesicles]/tumour/day) was injected in d-10, d-13 and d-16 subcutaneous
B16F10 on B6 mice, 4T1 on BALB/c mice, or CMS5m on BALB/c wild-type or
nude mice. At 18 days after tumour inoculation, grown B16F10 tumours (~2 cm in
diameter) were carefully excised in the B16F10-using case with scissors and the
skin was closed with surgical sutures. At 45 days after tumour inoculation, lung
metastasis of each tumour was observed.
Treatment with CD8+ T cell-derived EVs in vitro. DUC18 CD8 EVs, BALB TB
CD8 EVs, B6 CD8 EVs, BALB CD8 EVs or hPBMC EVs were added at 5 μg [2–4 ×
108 vesicles]/mL in 5 × 104 cells/mL CMS5a, B16 or bone-derived MSC culture, or
a mixed culture of 5 × 104 cells/mL CMS5a or B16 cells together with 5 × 104
cells/mL of bone-derived MSCs for 3 days at 1, 5 or 10 µg (1, 4 or 8 × 108 EVs)/mL.
At 3 days after cultivation, the obtained cells were subjected to observation of
spheroid formation and ﬂow cytometric analysis for counting total cell numbers
and the expression of CD140a and/or Sca-1, or annexin V, according to analysis
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Fig. 7 Destruction of mesenchymal tumour stroma by tumour-inﬁltrating CD8+ T cells. a DMSO- or GW4869-treated Thy-1.1+ DUC18 CD8+ T cells were
transferred intravenously into CMS5a-bearing BALB/c mice (n= 6 per group). The next day, resected tumours were sectioned and stained with the
indicated mAbs and DAPI. Each photo is a representative of 4–5 photos. Upper or lower photos of each group are the photos from the serial sections. The
dotted lines show the neovascularization areas. b Consistent with a, CMS5a sections of DMSO-treated Thy-1.1+ DUC18 CD8+ T cell-transferred groups
were stained with PE-conjugated Thy-1.1-speciﬁc mAb and FITC-conjugated Sca-1-speciﬁc mAb, and then the number of Thy-1.1+ cells in contact with/
without Sca-1+ cells was counted (**p< 0.01; error bars indicate SEM). The data were analysed by a two-tailed unpaired Student t-test. c At days 1, 2, 3, 5
and 7 after transferring untreated or GW4869-treated Thy 1.1+ DUC18 CD8+ T cells into CMS5a-bearing BALB/c wild-type or nude mice (n= 5 per group),
the resected tumours were sectioned and stained with the indicated mAbs and DAPI. Each photo is a representative of 3–4 photos. The dotted circles show
MSC areas overlapping with PE ﬂuorescence of CD140a with FITC ﬂuorescence of Sca-1. The number of overlapping areas of the untreated group on day 3
was signiﬁcantly different from that in the GW4869-treated group in BALB/c nu/nu- and BALB/c wild-type cases (*p< 0.05; n.s. not signiﬁcant; error bars
indicate SEM). The data were analysed by a two-tailed unpaired Student t-test
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of 5 μM camptothecin (Wako Pure Chemical Industries)-induced death of Jurkat
cells for 5 h.
Fluorescent immunohistochemistry. Frozen CMS5a and B16F10 tumour speci-
mens embedded in O.C.T compound (Sakura Finetech) were sectioned at a
thickness of 3 μm, air-dried for 2 h, ﬁxed with ice-cold acetone for 15 min, and
subjected to immunohistochemistry. After washing three times with PBS, the tissue
slides were incubated at 4 °C in blocking solution (PBS supplemented with 1% BSA,
5% Blocking One Histo [Nacalai Tesque]) and 0.2 µg/mL anti-mouse CD16/CD32
mAb (Biolegend) for 30 min. The tumour sections on the slides were then dual-
labelled with PE-conjugated and FITC-conjugated mAbs, or triple-stained with PE-
conjugated CD140a, APC-conjugated Sca-1 and FITC-conjugated Thy-1.1-speciﬁc
mAbs diluted with PBS supplemented with 1% BSA and 5% Blocking One Histo
for 1 h at room temperature in a humidiﬁed chamber. After washing three times
with PBS supplemented with 0.02% Tween-20, the slides were mounted in Prolong
Gold antifade reagent with/without DAPI (Life Technologies), and observed by
ﬂuorescence microscopy (BX53F; Olympus Co. Ltd.; Tokyo, Japan) or confocal
laser scanning microscopy (LSM780; Carl Zeiss, Oberkochen, Germany). The
photographs from PE-, FITC- and DAPI- or PE-, APC- and FITC-stained tissue
sections were merged by Photoshop elements software (Adobe Systems Software).
Observation of EV uptake in vivo and in vitro. DUC18 CD8 EVs were stained
with SYTO RNASelect (Life Technologies) and puriﬁed with PD SpinTrap G25
(GE Healthcare) as described above. SYTO RNASelect-stained EVs were injected
into day-14 subcutaneous CMS5a or B16 tumours at 20 μg per tumour. At 2 h after
injection, tumours were resected and suspended in 0.25% trypsin/0.02% EDTA.
After washing three times with PBS/10% FCS, the obtained tumour cell suspension
was stained with PE-conjugated anti-CD140a mAb and APC-conjugated anti-Sca-1
mAb (Biolegend), followed by ﬂow cytometric analysis.
CMS5a cells, B16 cells or bone-derived MSCs were cultured in four
compartments (Greiner Bio One) at an initial density of 1.0 × 104 cells/well
overnight. The next day, the SYTO RNASelect-labelled DUC18 CD8 EVs, BALB
CD8 EVs or hPBMC EVs were added to the cell cultures at a concentration of 5 μg
[2–4 × 108 vesicles]/mL. After 2 h, the cells were stained by LysoTracker Blue (Life
Technologies) and observed by confocal laser scanning microscopy (LSM780; Carl
Zeiss) equipped with 405-nm diode laser (for LysoTracker Blue) and 488-nm argon
laser (for SYTO RNASelect).
Analysis of EV miRNAs. EVs were dissolved with TRIzol reagent (Thermo Fisher
Scientiﬁc) and total miRNAs were puriﬁed using the miRNeasy mini kit (Qiagen).
Twenty µg of EVs were analysed with a 3D-gene miRNA microarray system
(Toray). According to the RNA sequences from miRBase, selected DUC18 CD8
EV-dominant miR-298–5p, 1943-5p and 5099; and BALB TB CD8 EV-dominant
miR-150-5p, 223-3p and 3470b were synthesised (Hokkaido System Science).
To study of activated caspase-3-mediated apoptosis, pan-caspase inhibitor
(Z-VAD-FMK: MedChem Express) or caspase-3 inhibitor (Z-DEVD-FMK: BD
Biosciences) was added to the MSC culture at 20 μM with 10 μg DUC18 CD8 EVs.
At 2 days after treatment, MSCs were stained with APC-conjugated annexin V and
analysed by ﬂow cytometry.
Small RNAs were isolated from EVs using miRNeasy mini kit (Qiagen)
according to the manufacturer’s directions. Reverse transcription of RNAs was
performed using the Mir-X miRNA First-Strand Synthesis Kit (Clonetech). RT-
qPCR was performed using the StepOnePlus Real-Time PCR system (Applied
Biosystems) with SYBR Advantage qPCR Premix (Clonetech) and synthetic
primers (GeneDesign: miR-298–5p; GGCAGAGGAGGGCTGTTCTTCCC). The
quantity of each miRNA was measured by the comparative Ct method (the ⊿⊿Ct
method). The level of each miRNA was normalised to that of a U6 snRNA control.
Western blot analysis. Cell proteins were extracted with cell lysis buffer (Cell
Signaling Technology) according to the manufacturer’s directions. EV and cell
proteins were dissolved in Laemmli sample buffer (Bio-Rad) with (for perforin,
granzyme B, Alix and Tsg101 detection) or without (for CD9 detection) 5% 2-ME,
and boiled for 5 min. Five μg of each protein sample and molecular weight markers
(MagicMark XP Standard: Thermo Fisher Scientiﬁc) were separated by 10%
polyacrylamide gel electrophoresis (e-PAGEL E-R10L: ATTO Corporation) using
SDS running buffer (Bio-Rad) at 40 mA for 60 min. The resulting gel was soaked
three times in transfer buffer (Bio-Rad) and proteins were transferred to an
Immobilon-P polyvinylidene ﬂuoride membrane (Merck) with a Trans-Blot SD
Semi-Dry Transfer Cell (Bio-Rad) at 1 mA/cm2 for 1 h. The obtained membrane
was blocked with 5% skim milk (Wako Pure Chemical Industries) in 0.05% TTBS
(TBS containing 0.05% Tween-20), and then treated with a primary mAb speciﬁc
for CD9 (eBioKMC8: eBioscience), perforin (eBioOMAK-D: Thermo Fisher Sci-
entiﬁc), granzyme B (21631: R&D Systems), Alix (3A9: Biolegend) or Tsg101
(EPR7130: Abcam) at 4 °C overnight. After washing three times with 0.05% TTBS,
the membrane was incubated with horseradish peroxidase-conjugated secondary
Ab speciﬁc for mouse IgG (GE Healthcare), rat IgG (R&D Systems) or rabbit IgG
(MBL International Corporation) at room temperature for 1 h. After washing four
times with 0.05% TTBS, the membranes were treated with ECL plus (GE
Healthcare) and visualised with LAS-4000 (Fujiﬁlm).
Statistical analysis. Data comparison between two groups were evaluated by the
analysis of two-tailed unpaired Student t-test. p values below 0.05 were considered
statistically signiﬁcant.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles or
from the corresponding authors on reasonable request.
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